Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

16.19
+0.57003.65%
Post-market: 16.190.00000.00%16:05 EDT
Volume:11.83M
Turnover:190.44M
Market Cap:18.57B
PE:-11.17
High:16.36
Open:15.81
Low:15.74
Close:15.62
Loading ...

Teva Pharmaceuticals Reports Continued Growth in 2024

TIPRANKS
·
30 Jan

Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track
·
30 Jan

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
30 Jan

Teva price target lowered to $23 from $26 at BofA

TIPRANKS
·
30 Jan

Why Teva Pharmaceutical Stock Is Sinking Today

Motley Fool
·
30 Jan

Teva falls -9.8%

TIPRANKS
·
29 Jan

Stock Track | Teva Pharmaceutical Plunges Over 11% on Weak Q4 Results and Gloomy 2025 Outlook

Stock Track
·
29 Jan

Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks
·
29 Jan

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

MT Newswires Live
·
29 Jan

Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?

Benzinga
·
29 Jan

Teva Swings to 4Q Loss as Revenue Falls

Dow Jones
·
29 Jan

Teva Pharm CFO Says

THOMSON REUTERS
·
29 Jan

Teva Pharm CEO Francis Says on Track for Huntington's Disease Drug Austedo to Hit $2.5 Bln in Revenue by 2027

THOMSON REUTERS
·
29 Jan

Teva Pharm CEO Francis Says Plan to Launch 7 Biosimilars With Originator Value of $20 Bln Between 2025 and 2027 in U.S.

THOMSON REUTERS
·
29 Jan

Teva Pharm CEO Francis Says to Launch 16 Complex Generics Drugs in 2025 and 2026

THOMSON REUTERS
·
29 Jan

Teva Pharm CFO Says Expects Branded Drugs Ajovy, Auestedo and Uzedy to Contribute About $2.8 Bln in Revenue in 2025

THOMSON REUTERS
·
29 Jan

Teva Pharm CEO Says in 2024, Generics Business Grew in All Regions for Second Year in a Row

THOMSON REUTERS
·
29 Jan

Teva Pharmaceutical Industries Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
29 Jan

Stock Track | Teva Pharmaceutical Plunges Over 7% in Pre-market Trading on Disappointing Q4 Results and Weak 2025 Outlook

Stock Track
·
29 Jan

Teva Pharmaceutical Q4 Non-GAAP Earnings, Revenue Fall; 2025 Outlook Issued

MT Newswires Live
·
29 Jan